Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Interim Management Statement

8 Aug 2007 07:00

Marchpole Holdings PLC08 August 2007 MARCHPOLE HOLDINGS PLC ("Marchpole", "the Company" or "the Group") Interim Management Statement Marchpole Holdings plc (LSE: MPH), the fast growing fashion brand management group,has today published its first Interim Management statement as required by the revised Listing Authority disclosure rules. The statement relates to the first 13 weeks of the new financial year, representing the period 1 April to 1 July 2007. The Board continues to believe, as reported on 28 June 2007, that the Group is well placed to withstand the termination of the YSL licence. For the purposes of this statement it is meaningless to draw comparisons withthe same period last year because of the changes in the composition of theGroup, notably the end of the YSL licence and the acquisitions of Homebody andGreenmark. Sales of Emanuel Ungaro and Ungaro Homme in Europe, including the UK, areencouraging and in line with expectations, and we remain confident that theUngaro brand will prove to be an adequate replacement for YSL. Orders for thefirst line, Emanuel Ungaro, have received a significant boost from thesuccessful Paris fashion show held on 29 June and will be further augmented bythe opening of three new flagship stores in Bucharest, Azerbaijan and Colombiain Spring 2008. On a like for like basis sales of Jean Charles de Castelbajac have increased byfive per cent and royalty income has more than doubled reflecting the newlicence agreements put in place over the last year. During the period a newdistribution agreement has been signed for Japan with Coronet, a member of theItochu Group and a new partnership entered into with Lee Cooper, one of theworld's original denim companies. These will enhance earnings in 2008/2009. Boateng sales and orders have grown from last year when performance was blightedby legal disputes and market confusion over the continuation of the licence. Asreported previously this dispute was settled in Marchpole's favour by the Courtof Appeal in December 2006. Greenmark has been successfully integrated into the Marchpole business model andis performing ahead of expectations. The retail environment in North America continues to be difficult and sales byModa America are lower than for the same 13 week period last year. On thepositive side margins have improved as a result of Marchpole's sourcingcapabilities. Our balance sheet remains strong following the improvements made during the yearto 31 March 2007. There have been no significant changes in the financialposition of the Group since the publication of the Annual Report for the yearended 31 March 2007. The resignation of John Harrison as Group Finance Director was announced on 26July 2007. A replacement is being sought and John will remain with the Groupuntil that process has been completed. For further information please contact: Marchpole Holdings plc:Michael Morris 020 7908 7777Executive Deputy Chairman Bell Pottinger:David Rydell/Emma Kent/Amy Rajendran 020 7861 3232 Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brandmanagement group that designs, produces and sells clothing and accessories forten globally recognised fashion labels. It operates in all of the world's mainmarkets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emmanuel Ungaro, Ungaro Homme,Jean Charles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol,Jean Charles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, JCDC/Lee Cooper and Homebody and Homemummy - Marchpole is renowned for its integrated approach to brandmanagement, taking a brand from concept to design studio to the customerinterface. - The Group has grown considerably in the past four years, from alicensee with one core licence (YSL menswear) - to today's internationalbusiness that manages its brands across a multitude of clothing lines andaccessories - Marchpole's acquisition (March 2006) of Moda America - the USlicensee for leading designer Emanuel Ungaro - provided further growthopportunities in the UK and America and strengthened the Company's relationshipwith Ungaro - The acquisition also enabled the Company to launch the Ungaro brand,already established by Marchpole in Europe and Asia, into the US, Canada andSouth America. The acquisition has also enabled the Company to re-launch JCCinto America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, animporter and wholesaler of ladies shoes who currently supply in excess of 2.5million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.